91色情片

Several doctors and patients in a busy ICU Several doctors and patients in a busy ICU

Simple patch can make medications safer and more effective

Play icon
Tom Melville
Tom Melville,

91色情片 researchers have helped design a simple, wearable patch to give clinicians up-to-the-minute readouts of a medication鈥檚 levels in the body, offering a new era of precision dosing.

Vancomycin is the antibiotic doctors reach for when almost nothing else will work.

It鈥檚 used in hospitals for serious drug-resistant infections, or for when an infection is spreading through the patient鈥檚 bloodstream.

It's commonly used in hospitals around the world, but it鈥檚 also notoriously tricky to dose: too little and it won鈥檛 knock out the infection, too much and the patient risks kidney damage or even death.

Right now, dosage levels are monitored by repeated blood tests, an invasive and time-consuming process that can鈥檛 always give clinicians the data they need in time.

Up to 40% of patients receiving vancomycin develop an acute kidney injury.

Hoping to solve this issue, 91色情片 and international researchers working alongside Australian diagnostics company Nutromics developed a minimally invasive patch that tracks the antibiotic in patients every five minutes.

The team have , and say its success demonstrates that the major scientific and safety challenges have been solved.

鈥淭his is such an exciting breakthrough,鈥 says Scientia Professor Justin Gooding from the 91色情片 School of Chemistry, who helped develop the tool.

鈥淚t means we can monitor people on the timescales needed so we can make sure they get the best treatment, the most effective treatment, and the safest treatment,鈥 he says.

Trial participants reported that the patch application process was nearly painless, making it a much more comfortable alternative to standard blood testing. Photo: Supplied Nutromics

A 'lab-on-a-patch'

The device uses synthetic DNA-based sensors to measure dosage levels, building on lab research demonstrating their potential.

The sensors, known as 鈥渁ptamers鈥, bind to target molecules in the human body and sit on microneedles in the patient鈥檚 arm that sample fluid from beneath the skin.

Patients reported that this process was nearly painless, making the patches much more comfortable than standard blood draws.

The aptamer technology can be tweaked to test for other drugs and illnesses, and Nutromics is working on other diagnostic and monitoring patches.

鈥淪epsis is one of the leading causes of preventable death,鈥 says Scientia Professor Gooding.

鈥淭he problem with sepsis is its symptoms are very similar to other infections, so how do we know for sure you've got sepsis?

鈥淚f we could measure sepsis markers in the body, then we could treat it very effectively and quickly using antibiotics. It would save a lot of lives.

鈥淏ut the concept can keep going on. If you think of any drug, any small molecule, in principle, this technology could be used to monitor for it.鈥

It means we can monitor people on the timescales needed so we can make sure they get the best treatment, the most effective treatment, and the safest treatment.
Scientia Professor Justin Gooding, study co-author

Out of the lab and into the hospital

Researchers had long believed aptamer technology could be used as a diagnostic tool, with previous studies on laboratory animals demonstrating their potential.

Working with Nutromics, however, gave researchers the opportunity to help design a readily manufacturable device that could turn their lab work into real-world impact.

鈥淭he reason I'm involved in this is this is really a once in a lifetime opportunity,鈥 says Scientia Professor Gooding.

鈥淚f this company gets to market and this technology proves to be useful, it will change the way we do health care.鈥

Getting ideas out of academic research labs isn鈥檛 always easy, though. Professor Gooding says this is why industry partners are so crucial.

鈥淲hat academics do is come up with the ideas and show that they have potential. If they've got commercial potential, other people should take them through to market,鈥 he says.

鈥淵ou need people who know how to translate an idea into a product.鈥

Nutromics CEO Peter Vranes also stresses the importance of partnerships between academia and industry, noting that a research institution鈥檚 true power lies in discovery, not always in translating those discoveries.

鈥淲hen trying to accomplish a world-first as we have in this study, you need to combine exceptional discovery with translation,鈥 he says.

鈥淏y collaborating with leading research institutions like 91色情片, we do exactly that: successfully create real-world solutions that improve patient care.鈥

Trials of the patch are underway in ICUs across Australia and Nutromics hopes to get US regulatory approval by next year.

The company is also working to adapt the technology to other conditions with the hope that real-time monitoring for cardiology, or even the ability to quickly triage patients in emergency departments, might one day become common.

Media enquiries

Tel: +61 432 912 060
Email: tom.melville@unsw.edu.au